Share on StockTwits

Equities researchers at Leerink Swann cut their target price on shares of Karyopharm Therapeutics (NASDAQ:KPTI) from $63.00 to $60.00 in a research report issued on Friday. Leerink Swann’s target price indicates a potential upside of 68.92% from the company’s current price.

In other Karyopharm Therapeutics news, major shareholder Marcin Czernik sold 21,570 shares of the stock on the open market in a transaction dated Wednesday, July 30th. The shares were sold at an average price of $36.20, for a total transaction of $780,834.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Major shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Shares of Karyopharm Therapeutics (NASDAQ:KPTI) traded up 0.11% during mid-day trading on Friday, hitting $35.52. 171,379 shares of the company’s stock traded hands. Karyopharm Therapeutics has a 52-week low of $15.50 and a 52-week high of $47.98. The stock’s 50-day moving average is $38.15 and its 200-day moving average is $34.05. The company’s market cap is $1.057 billion.

Karyopharm Therapeutics (NASDAQ:KPTI) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($1.02) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.50) by $0.52. On average, analysts predict that Karyopharm Therapeutics will post $-2.01 earnings per share for the current fiscal year.

Separately, analysts at Oppenheimer downgraded shares of Karyopharm Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Monday, July 7th. One analyst has rated the stock with a hold rating and two have assigned a buy rating to the company. Karyopharm Therapeutics presently has an average rating of “Buy” and a consensus price target of $52.67.

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company focused on the discovery and development of drugs directed against nuclear transport targets for the treatment of cancer and other major diseases.

Receive News & Ratings for Karyopharm Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.